Brokerages Set Heska Corp (HSKA) PT at $113.25

Heska Corp (NASDAQ:HSKA) has been assigned a consensus recommendation of “Buy” from the ten analysts that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have issued ratings on the stock in the last year is $113.25.

Several research firms recently commented on HSKA. BidaskClub cut Heska from a “strong-buy” rating to a “buy” rating in a research note on Friday. ValuEngine cut Heska from a “buy” rating to a “hold” rating in a research note on Thursday. Canaccord Genuity reissued a “buy” rating and issued a $123.00 price objective (up previously from $115.00) on shares of Heska in a research note on Friday, June 15th. TheStreet raised Heska from a “c+” rating to a “b-” rating in a research note on Thursday, May 31st. Finally, Zacks Investment Research cut Heska from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 23rd.

In other news, Director G Irwin Gordon sold 3,400 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The stock was sold at an average price of $106.18, for a total value of $361,012.00. Following the transaction, the director now owns 19,906 shares in the company, valued at $2,113,619.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Nancy Wisnewski sold 750 shares of the firm’s stock in a transaction that occurred on Friday, June 8th. The shares were sold at an average price of $106.50, for a total value of $79,875.00. Following the completion of the transaction, the executive vice president now owns 34,873 shares in the company, valued at approximately $3,713,974.50. The disclosure for this sale can be found here. Insiders sold 26,202 shares of company stock valued at $2,752,523 in the last three months. Insiders own 14.70% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Bank of New York Mellon Corp lifted its holdings in shares of Heska by 110.1% in the fourth quarter. Bank of New York Mellon Corp now owns 210,669 shares of the medical research company’s stock valued at $16,897,000 after purchasing an additional 110,391 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Heska by 13.3% in the fourth quarter. Rhumbline Advisers now owns 14,785 shares of the medical research company’s stock valued at $1,186,000 after purchasing an additional 1,731 shares in the last quarter. Ranger Investment Management L.P. lifted its holdings in shares of Heska by 436.0% in the fourth quarter. Ranger Investment Management L.P. now owns 166,583 shares of the medical research company’s stock valued at $13,362,000 after purchasing an additional 135,505 shares in the last quarter. Redmile Group LLC bought a new position in shares of Heska in the fourth quarter valued at approximately $15,753,000. Finally, Fred Alger Management Inc. lifted its holdings in shares of Heska by 27.3% in the fourth quarter. Fred Alger Management Inc. now owns 139,120 shares of the medical research company’s stock valued at $11,159,000 after purchasing an additional 29,844 shares in the last quarter. Institutional investors own 89.16% of the company’s stock.

Heska opened at $102.10 on Tuesday, according to MarketBeat. Heska has a one year low of $56.59 and a one year high of $115.00. The company has a market cap of $787.51 million, a P/E ratio of 49.32 and a beta of 0.80.

Heska (NASDAQ:HSKA) last released its earnings results on Friday, May 4th. The medical research company reported $0.28 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.12). Heska had a return on equity of 13.30% and a net margin of 5.57%. The business had revenue of $32.77 million for the quarter, compared to analyst estimates of $31.65 million. analysts forecast that Heska will post 1.68 EPS for the current fiscal year.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply